Now showing items 1-1 of 1

    • Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. 

      Lorente, D; Ravi, P; Mehra, N; Pezaro, C; Omlin, A; Gilman, A; Miranda, M; Rescigno, P; Kolinsky, M; Porta, N; Bianchini, D; Tunariu, N; Perez, R; Mateo, J; Payne, H; Terstappen, L; IJzerman, M; Hall, E; de Bono, J (2018-03)
      BACKGROUND: Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic ...